medigraphic.com
ISSN 1561-3119 (Electronic)

2020, Number 4

<< Back Next >>

Rev Cubana Pediatr 2020; 92 (4)

Comorbility in patients with neurodevelopmental disorders

García GRJ, Robinson AMÁ

Language: Spanish
References: 59
Page: 1-22
PDF size: 583.52 Kb.


ABSTRACT

Introduction: The term “neurodevelopmental disorder” includes different combinations of deficiencies in the abilities expected for the chronological age of a child, taking into account the motor, speech, socialization, sensorial and sphincter control’s scopes, and in the affected patients can be related some diseases (comorbility).
Objective: To examine the main chronic comorbilities that can present in patients with neurodevelopmental disorders.
Methods: The search sources were computerized databases as: PubMed, Ebsco, SciELO; also references identified in the reviewed articles and that were considered as important and with scientific validity, with ten or less years of being published. 42 of 59 were published in the last five years. There were used for the search the following keywords in Spanish, English and French languages, depending on the source: neurodevelopmental disorders, children development, comorbility, autistic disorder.
Results: The most frequent comorbilities or the ones which are important due to their impact in the life of patients with neurodevelopmental disorders are: epilepsy, audition and sight disorders, mental conditions, deglutition difficulty and poor nutritional state.
Final considerations: The occurrence of comorbility in patients with neurodevelopmental disorders is frequent; it can be present in the nervous system or in other systems of the body, and it contributes for the life quality of these patients being less affected.


REFERENCES

  1. Donkelaar HJ, van der Vliet T. Overview of the development of the human brain and spinal cord. In: Donkelaar HJ, Lammens M, Hori A. editors. Clinical neuroembriology. Development and Developmental Disorders of the Human Central Nervous System. Berlin: Springer; 2006. p. 1-40.

  2. Portal Infomed. Descriptor en Ciencias de la salud. Conceptos y definiciones. La Habana. Portal; 2020 [acceso 28/04/2019]: Disponible en: Disponible en: http://decs.bvs.br/E/homepagee.htm

  3. García García RJ. Principales manifestaciones clínicas y pronóstico de las enfermedades del sistema nervioso central. En: Colectivo de autores, editores científicos. Pediatría. Diagnóstico y tratamiento. 3ra ed. La Habana: Editorial Ciencias Médicas; 2016. p. 272-4.

  4. Galán-López IG, Lascarez-Martínez S, Gómez-Tello MF, Galicia-Alvarado MA. Abordaje integral en los trastornos del neurodesarrollo. Rev Hosp Jua Mex. 2017;84(1):19-25.

  5. Artigas-Pallarés J, Guitart M, Gabau-Vila E. Bases genéticas de los trastornos del neurodesarrollo. Rev Neurol. 2013;56 (Supl 1):S23-S34.

  6. Norbury CF, Vamvakas G, Gooch D, Baird G, Charman T, Simonoff E, et al. Language growth in children with heterogeneous language disorders: a population study. J Child Psychol Psychiatr. 2017;58(10):1092-105. doi: 10.1111/jcpp.12793.

  7. Velde A, Morgan C, Novak I, Tantsis E, Badawi N.nEarly Diagnosis and Classification of Cerebral Palsy: An Historical Perspective and Barriers to an Early Diagnosis. J. Clin. Med. 2019;8(1599). doi: 10.3390/jcm8101599

  8. Hubert-Dibon G, Bru M, Gras Le Guen C, Launay E, Roy A. Health-Related Quality of Life for Children and Adolescents with Specific Language Impairment: A Cohort Study by a Learning Disabilities Reference Center. PLoS ONE 2016;11(11):e0166541. doi: 10.1371/journal.pone.0166541

  9. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522-30.

  10. Espinosa-Jovel C, Toledano R, Aledo-Serrano A, García-Morales I, Gil-Nagel A. Epidemiological profile of epilepsy in low income populations. Seizure. 2018;56:67-72.

  11. Serrano-Castro PJ, Mauri-Llera JA, Hernández-Ramos FJ, Sánchez-Álvarez JC, Parejo-Carbonell B, Quiroga-Subirana P, et al. Adult prevalence of epilepsy in Spain: EPIBERIA, a population-based study. Sci World J. 2015;2015:602710.

  12. Lee TMC, Chan JKP. Factores que afectan el estado cognitivo de personas que sufren epilepsia. Rev Neurol. 2002;34(9):861-5.

  13. Espie CA, Watkins J, Curtice L, Espie A, Duncan R, Ryan JA, et al. Psychopathology in people with epilepsy and intelectual disability; an investigation of potential explanatory variables. J Neurol Neurosurg Psychiatr. 2003;74:1485-92.

  14. Tuchman RF, Moshé SL, Rapin I. Trastornos del neurodesarrollo y epilepsia. Rev Neurol. 2005;40(Supl 1):S3-S10.

  15. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol. 2002;44:724-8.

  16. Scheffer IE, Zhang Y, Gecz J, Dibbens L. Genetics of the epilepsies: Genetic twists in the channels and other tales. Epilepsia. 2010;51(Suppl.1):33-6. doi: 10.1111/j.1528-1167.2009.02440.x.

  17. Thomas-Sohl KA, Vaslow DF, Maria BL. Sturge-Weber Syndrome: A Review. Pediatr Neurol. 2004;30:303-10.

  18. Hirose S, Mitsudome A. X-linked mental retardation and epilepsy: pathogenetic significance of ARX mutations. Brain Dev. 2003;25(3):161-5.

  19. Afawi Z, Oliver KL, Kivity S, Mazarib A, Blatt I, Neufeld MY, Katherine L. Multiplex families with epilepsy. Neurology. 2016;86(8):713-22. doi: 10.1212/WNL.0000000000002404.

  20. Lee S, Baek M, Lee Y. Lennox-Gastaut Syndrome in Mitochondrial Disease. Yonsei Med J. 2019;60(1):106-14. doi.org/10.3349/ymj.2019.60.1.106.

  21. Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies. Pharmacol Rev. 2018;70:142-73. doi.org/10.1124/pr.117.014456

  22. Lorente Hurtado I. La parálisis cerebral. Actualización del concepto, diagnóstico y tratamiento. Pediatr Integr. 2007;XI(8):687-98.

  23. Vázquez Vela CC, Vidal Ruiz CA. Parálisis cerebral infantil: definición y clasificación a través de la historia. Rev Mex Ortop Ped. 2014;16(1);6-10.

  24. Kariuki SM, Abubakar A, Stein A, Marsh K, Newton CR. Prevalence, causes, and behavioral and emotional comorbidities of acute symptomatic seizures in Africa: A critical review. Epilep Open. 2017;2(1):8-19. doi: 10.1002/epi4.12035.

  25. Soul JS. Acute symptomatic seizures in term neonates: etiologies and treatments. Semin Fetal Neonatal Med. 2018;23(3):183-90. doi: 10.1016/j.siny.2018.02.002.

  26. García García RJ. Tratamiento del paciente epiléptico en la atención primaria de salud. En: Morales Chacón L, Kochen S, editores. Epilepsias en el primer nivel de atención de salud. Buenos Aires: Sara Silvia Kochen; 2017. p. 81-109.

  27. Martínez-García SM, Hernández-Da Mota SE, Rubio-Rangel A, Rojas-Flores I, Vieyra-López ME, Martínez-Castellanos MA, et al. Neurodevelopment in patients with retinopathy of prematurity treated with intravitreal bevacizumab. Case series. Cir Cir. 2017;85:478-84.

  28. Ximena Katz V. Prematuridad y visión. Rev Med Clin Condes. 2010;21(6):978-83.

  29. VanBeeck Calkoen EA, Engel MS, van de Kamp JM, Yntema HG, Goverts ST, Mulder MF, et al. The etiological evaluation of sensorineural hearing loss in children. Eur J Pediatr. 2019;178:1195-205. doi.org/10.1007/s00431-019-03379-8

  30. Rodillo E. Trastornos por déficit de atención e hiperactividad (TDAH) en adolescentes. Rev Med Clin Condes. 2015;26(1):52-9.

  31. Fernández-Jaén A, Martín Fernández-Mayoralas D, Fernández-Perrone AL, Jiménez A, Albert J, López-Martín S, et al. Neurodesarrollo y fenocopias del trastorno por déficit de atención/hiperactividad: diagnóstico diferencial. Rev Neurol. 2018;66(Supl 1):S103-S107.

  32. Hervás Zúñiga A, Balmaña N, Salgado M. Los trastornos del espectro autista (TEA). Pediatr Integr. 2017;XXI(2):92-108.

  33. Hervás Zuñiga A. Desregulación emocional y trastornos del espectro autista. Rev Neurol. 2017;64(Supl 1):S17-25.

  34. Rico-Moreno J, Tárraga-Mínguez R. Comorbilidad de TEA y TDAH: revisión sistemática de los avances en investigación. An Psicol. 2016 [acceso 12/04/2019];32(3):810-9. doi: /bhttp://dx.doi.org/10.6018/analesps.32.3.217031

  35. Ludlow C. Central nervous system control of interaction between vocalization and respiration in mammals. Head Neck. 2011;(33):S21-S25.

  36. Ludlow CL. Laryngeal Reflexes: Physiology, Technique and Clinical Use. J Clin Neurophysiol. 2015;32(4):284-93. doi: 10.1097/WNP.0000000000000187

  37. Yuksel ES, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: cough, asthma, laryngitis, chestpain. Swiss Med Wkly. 2012;(142):135-44.

  38. Salinas-Valdebenito L, Núñez Farias AC, Milagros A, Escobar RG. Caracterización clínica y evolución tras la intervención terapéutica de trastornos de deglución en pacientes pediátricos hospitalizados. Rev Neurol. 2010;50:139-44.

  39. Huiracocha Tutiven ML, Rojas Sulbarán RD, Huiracocha Tutivén MS. Auscultación cervical: alternativa no invasiva en el diagnóstico de disfagia en niños con problemas del neurodesarrollo. Rev Facultad Ciencias Médicas Universidad de Cuenca. 2015;33(2):80-8.

  40. Luna Hernández JA, Hernández Arteaga I, Rojas Zapata AF, Cadena Chala MC. Estado nutricional y neurodesarrollo en la primera infancia. Rev Cubana Salud Pública 2018 [acceso 12/4/2019];44(4):169-85. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0864-34662018000400169&lng=es&nrm=iso

  41. Cárdenas E. La educación y atención integral para el desarrollo de la niñez menor de 3 años en Costa Rica: una deuda del estado costarricense. Actualidades Investigativas Educac. 2016;16(1):1-23.

  42. Medina M, Caro I, Muñoz P, Leyva P, Moreno J, Vega S. Neurodesarrollo infantil: características normales y signos de alarma en el niño menor de cinco años. Rev Peru Med Exp Salud Pública. 2015;32(3):565-73.

  43. Mudd AT, Dilger RN. Early-Life Nutrition and Neurodevelopment: Use of the Piglet as a Translational Model. Adv Nutr. 2017;8(1):92-104. doi: 10.3945/an.116.013243.

  44. Beluska-Turkan K, Korczac R, Hartell B, Moskal K, Maukonen J, Alexander DE, et al. Nutritional Gaps and Supplementation in the First 1000 Days. Nutrients. 2019;11(12):2891. doi: 10.3390/nu11122891

  45. Das JK, Salam RA, Hadi YB, Sheikh SS, Bhutta AZ, Prinzo ZW, et al. Preventive lipid‐based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. Cochrane Database Syst Rev. 2019 May; 2019 (5):CD012611. doi: 10.1002/14651858.CD012611.pub3

  46. Daniel AI, Bandsma RH, Lytvyn L, Voskuijl WP, Potani I, Heuvel M. Psychosocial stimulation interventions for children with severe acute malnutrition: a systematic review. J Glob Health. 2017;7(1):010405. doi: 10.7189/jogh.07.010405

  47. Huiracocha-Tutiven ML, Orellana-Paucar A, Abril-Ulloa V, Huiracocha-Tutiven MS, Palacios-Santana G, Blume S. Child Development and Nutritional Status in Ecuador. Glob Pediatr Health. 2019;6:2333794X18821946. doi: 10.1177/2333794X18821946

  48. Leiva Plaza, B. Algunas consideraciones sobre el impacto de la desnutrición en el desarrollo cerebral, inteligencia y rendimiento escolar. Arch Latinoam Nutr. 2001;51(1):64-71.

  49. McQuire C, Hassiotis A, Harrison B, Pilling S. Pharmacological interventions for challenging behaviour in children with intellectual disabilities: a systematic review and meta-analysis. BMC Psychiatry. 2015;15:303. doi: 10.1186/s12888-015-0688-2

  50. Brodie MJ, Besag F, Ettinger AB, Mula M, Gobbi G, Comai S, et al. Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based Review. Pharmacol Rev. 2016; 68(3):563-602. doi: 10.1124/pr.115.012021.

  51. Hanayaka R, Arita K. The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications. Neurol Med Chir. (Tokyo). 2016;56(5):205-20. doi: 10.2176/nmc.ra.2015-0344

  52. Bélanger SA, Andrews D, Gray C, Korczak D. ADHD in children and youth: Part 1-Etiology, diagnosis, and comorbidity. Paediatr Child Health. 2018;23(7):447-53. doi: 10.1093/pch/pxy109

  53. Storebø OJ, Pedersen N, Ramstad E, Kielsholm ML, Nielsen SS, Krogh HB, et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents-assessment of adverse events in non‐randomised studies. Cochrane Database Syst Rev. 2018; 2018(5):CD012069. doi: 10.1002/14651858.CD012069.pub2

  54. García García RJ. Epilepsia y comorbilidad. En: Morales Chacón L, Kochen S. editores. Epilepsias en el primer nivel de atención de salud. Buenos Aires: Sara Silvia Kochen; 2017. p. 121-34.

  55. Ko C, Kim N, Kim E, Song DH, Cheon K. The effect of epilepsy on autistic symptom severity assessed by the social responsiveness scale in children with autism spectrum disorder. Behav Brain Funct. 2016;12:20. doi: 10.1186/s12993-016-0105-0

  56. Luz-Escamilla L, Morales-González JA. Association between Interictal Epileptiform Discharges and Autistic Spectrum Disorder Brain Sci. 2019;9(8):185. doi: 10.3390/brainsci9080185

  57. Stepanova E, Dowling S, Phelps M, Findling RL. Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents. Dialogues Clin Neurosci. 2017 [acceso 24/02/2020];9(4):395-402. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789216/

  58. Ji N, Findling RL. An update on pharmacotherapy for autism spectrum disorder in children and adolescents. Curr Opin Psychiatry. 2015;28(2):91-101.

  59. Subramanyam AA, Mukherjee A, Dave M, Chavda K. Clinical Practice Guidelines for Autism Spectrum Disorders. Indian J Psychiatry. 2019;61(Suppl 2):54-69. doi: 10.4103/psychiatry.IndianJPsychiatry_542_18




2020     |     www.medigraphic.com